Biogen CEO Michel Vounatsos To Step Down After Commercial Failure of Alzheimer's Drug

Edward Kim  |

Image: Michel Vounatsos. Source: Biogen

Biogen (BIIB) announced Tuesday that it has begun a search for a new CEO in the wake of the commercial failure of its controversial Alzheimer's disease drug, Aduhelm.

The announcement of the impending departure of Michel Vounatsos was buried on page 6 of the company's 19-page first quarter earnings release.

The company said Vounatsos would keep the seat warm until a successor was named.

Biogen said it would "substantially eliminate commercial infrastructure for Aduhelm," i.e., it would no longer spend any money to market the drug.


The FDA approved Aduhelm in June 2021 against the strong recommendation of its Peripheral and Central Nervous System Drugs Advisory Committee.

That committee voted resoundingly against approval, stating that the data did not support its effectiveness in treating Alzheimer's disease.

When the FDA shockingly granted approval, 3 of the 11 members of the committee resigned, including David S. Knopman, a neurologist at the Mayo Clinic, Joel S. Perlmutter, a neurologist at Washington University in St. Louis, and Aaron Kesselheim, a professor of Medicine at Harvard Medical School.

Betting Against Elon Musk Has Not Been Profitable

In his resignation letter, Kesselheim called the Aduhelm approval "probably the worst drug approval decision in U.S. history."

Kesselheim further stated, "It is clear to me that FDA is not presently capable of adequately integrating the Committee's scientific recommendations into its approval decisions."

Investment thesis

Click to enlarge

This is usually where we give you some reasons to be optimistic about a stock, but we don't recommend investors try to be brave here.

Elsewhere in Biogen's Q1 report, the company reported Q1 sales of Aduhelm of only $2.8 million, significantly below expectations. Beyond the controversy behind the drug, Medicare determined that it would only pay for the drug for people who received it as part of a clinical trial, further capping any realistic upside.

Biogen stock has lost more than 55% since peaking last summer, and we see no reason to fight the tape, at least until a new CEO is named.

Further, investors should expect significant changes structurally at Biogen, including the possibility of divesting certain R&D programs while accelerating others. Until we have any visibility about what those changes might entail, we can't recommend being long this stock.


Source: Equities News


Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

Trending Articles

Modine Posts Strong Rebound in Fiscal Q4, Raises 2023 Guidance
Dollar Tree Posts Record First Quarter, Leads Nasdaq Gainers
Kohl's Still in Play To Be Acquired
Market Conditions Driving Higher Base Level for VIX Volatility Index
Will New AT&T, Dish Co-opetition Deal Work: Jeff Kagan
Cisco Down 12% in Premarket Trading Thursday After Top Line Miss and Lower Forecast
Under Armour CEO Patrik Frisk To Step Down in Surprise Announcement
Target Hits 52-Week Low After Missing Badly on First Quarter Earnings

Market Movers

Sponsored Financial Content